Interviews

Andrew Leitner, MD, of City of Hope, discusses the challenges of integrating supportive care into cancer treatment and proposes solutions to improve access for patients from underserved communities.

Laurence Sperling, MD, executive director of the Million Hearts initiative at the CDC and CMS, shared insight into population health strategies to address cardiovascular disease (CVD) prevention in at-risk populations.

Linda Bosserman, MD, PhD, FASCO, FACP, of City of Hope, emphasizes the need for a sustainable health care system that balances cost with care so patients can achieve the best survival and quality of life after a cancer diagnosis.

Strategies for integrated delivery networks (IDNs) to manage rising biologic medication costs while ensuring financial sustainability and patient outcomes are discussed during an interview with Elie M. Bahou, PharmD, MBA, senior vice president and system chief pharmacy officer at Providence.

Amy Peterson, MD, professor in the Department of Pediatrics at the University of Wisconsin, discussed current pediatric lipid screening guidelines and the potential evolution of pediatric lipid screening in the coming years.

Andrew Leitner, MD, City of Hope, highlights the essential role of supportive care in improving the quality of life of patients with cancer undergoing treatment.

JT Lew, PharmD, MBA, managed care pharmacist at MultiCare Health System, spoke to the impacts of processes such as prior authorization and step therapy requirements in the realm of multiple sclerosis (MS).

Linda Bosserman, MD, PhD, FASCO, FACP, of City of Hope, highlights challenges in cancer care, focusing on improving access to accurate diagnoses and treatments, promoting patient-centered approaches, and fostering collaboration to achieve better outcomes.

Arash Mostaghimi, MD, MPA, MPH, assistant professor of dermatology, director of the inpatient dermatology consult service, and codirector of the Complex Medical Dermatology Fellowship at Brigham & Women's Hospital, draws attention to the challenges in identifying specific treatment targets in alopecia areata and the development of effective outcome measures for clinical trials.

September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our fourth episode, we speak with Amy Herschell, PhD, and Jessica Meyers, MSEd.

Demonstration projects to show accurate use of artificial intelligence (AI) in cancer care are important to prevent a loss of credibility in the technology, explained Glenn Balasky, executive director, Rocky Mountain Cancer Centers.

Joseph Alvarnas, MD, of City of Hope, discusses how he envisions the future of cancer care over the next decade.

April Armstrong, MD, MPH, chief of dermatology, UCLA, discusses clinical trial findings from the phase 2b study on zasocitinib.

This interview accompanies the third podcast in our National Recovery Month series with Kim MacDonald-Wilson, ScD, CPRP, senior program director, Recovery and Wellness Transformation, and Tracy Carney, CPS, CPRP, senior recovery and resiliency specialist, Community Care Behavioral Health Organization.

Joseph Alvarnas, MD, of City of Hope, recaps yesterday's Institute for Value-Based Medicine® (IVBM) event on value-based oncology care, emphasizing patient-centered approaches and how attendees can apply these insights in their daily practice.

Anant Madabhushi, PhD, executive director for the Emory Empathetic AI for Health Institute, discusses the potential of artificial intelligence (AI) for myeloma research at the 2024 International Myeloma Society conference.

On this episode of Managed Care Cast, we're talking with the author of a study published in the September 2024 issue of The American Journal of Managed Care® that explored the factors consumers consider essential for an adequate provider network.

Chairs and presenters from the 2024 World Conference on Lung Cancer comment on their favorite parts about attending this meeting each year.

Toby Maher, MD, PhD, professor of clinical medicine, Keck Medicine of USC, discusses recent advancements in clinical trials for patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).

The principal goal of therapies for multiple myeloma, which remains incurable, is to extend progression-free survival, but challenges remain bringing chimeric antigen receptor T-cell therapy to the world, explains Leland Metheny, MD, lead investigator for the phase 1 BAFF CAR T clinical trial, University Hospitals Seidman Cancer Center.

Jennifer Green, MD, of Duke University, stresses the need for high-risk patients with diabetes to use medications that prevent future cardiovascular and kidney events.

The first overall survival analysis of the KEYNOTE-522 trial showed positive outcomes with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab monotherapy vs neoadjuvant chemotherapy alone in high-risk early-stage triple-negative breast cancer (TNBC).

Nicolas Girard, MD, head of the Curie-Montsouris Thorax Institute, discusses patient-reported outcomes (PROs) from the phase 2 LUMINOSITY trial of telisotuzumab vedotin (Teliso-V) in non–small cell lung cancer (NSCLC).

September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In this third episode, we speak with Kim MacDonald-Wilson, ScD, CPRP, and Tracy Carney, CPS, CPRP.

Mirvetuximab soravtansine showed high evidence of efficacy in heavily pretreated FRα-positive, platinum-sensitive ovarian cancer, which is a challenging patient population to treat, Angeles Alvarez Secord, MD, MHSc, gynecologic oncologist at Duke Health, said.

Sheela Rao, MBBS, FRCP, MD, consultant medical oncologist at the Royal Marsden Hospital, discussed the findings of the POD1UM-303/InterAACT2 trial of retifanlimab plus chemotherapy for squamous cell carcinoma of the anal canal (SCAC).

Davey Daniel, MD, chief medical officer at OneOncology, stresses the need for real-world evidence in genomic testing to improve patient outcomes and cost-effectiveness.

Jonathan Riess, MD, MS, director of thoracic medicine at UC Davis Health, gave insight into the rationale and efficacy data for combining cancer vaccine IO102-IO103 with pembrolizumab in advanced squamous cell carcinoma of the head and neck.

Deepened, persistent responses were seen in the long term among patients with advanced melanoma treated with fianlimab and cemiplimab, Meredith McKean, MD, MPH, director of melanoma and skin cancer research for Sarah Cannon Research Institute, explained.

Speakers at the 2024 meeting of ERS—The European Respiratory Society Congress share their favorite parts of the conference.